文献速递头痛与眩晕

在2-4种既往预防治疗失败的发作性偏头痛参与者中厄瑞奴单抗的疗效与安全性:LIBERTY 3年研究

Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study.
PubMed 文献 · Neurology · 2024-04-26

LIBERTY研究评估厄瑞奴单抗在发作性偏头痛且2-4种既往预防治疗失败的参与者中的疗效与安全性,报告开放标签延伸期3年暴露结果。参与者每月接受140 mg厄瑞奴单抗治疗3年,主要结局包括月偏头痛天数(MMD)减少≥50%的比例、MMD自基线的平均变化及耐受性与安全性。结果显示疗效持续3年,未观察到新的安全信号。

要点

  • 在总体人群中,79/151名有有效数据的参与者在第168周达到MMD减少≥50%(即应答者)。
  • 持续厄瑞奴单抗组第12周应答者中26/35(74.3%)在至少一半OLEP访视中维持应答。
  • 总体MMD自基线平均(SD)变化在第168周为-4.4(3.9)天,3年间持续改善。

核心结论

  • 厄瑞奴单抗(140 mg)在发作性偏头痛且2-4种既往预防治疗失败的参与者中显示出持续3年的疗效,未观察到新的安全信号。

研究设计与样本

  • LIBERTY研究开放标签延伸期(OLEP):完成12周双盲治疗期(DBTP)的参与者可进入OLEP,每月接受140 mg厄瑞奴单抗治疗3年。
  • 共240/246(97.6%)名参与者进入OLEP,168/240(70.0%)完成研究(持续厄瑞奴单抗组85/118完成,安慰剂转换组83/122完成)。

主要发现

  • 总体人群中,79/151名(52.3%)有有效数据的参与者在第168周达到MMD减少≥50%(应答者)。
  • 持续厄瑞奴单抗组中,35/117名(29.9%)在DBTP第12周为≥50%应答者,其中26/35名(74.3%)在至少一半OLEP访视中维持≥50%应答。
  • 持续厄瑞奴单抗组第12周未达应答的82/117名(70.1%)中,17/82名(20.7%)在至少一半OLEP访视中转为≥50%应答者。
  • 安慰剂-厄瑞奴单抗组第12周未达应答的103/120名(85.8%)中,转换后42/103名(40.8%)在至少一半OLEP访视中转为≥50%应答者。
  • 总体MMD自基线平均(SD)变化在第168周为-4.4(3.9)天,3年间持续改善;最常见治疗中出现的不良事件(每100人年)为鼻咽炎(28.8)、流感(7.5)和背痛(5.8)。

关键数值与推荐

  • 总体人群中52.3%(79/151)有有效数据的参与者在第168周达到MMD减少≥50%。
  • 持续厄瑞奴单抗组第12周应答者中74.3%(26/35)在至少一半OLEP访视中维持应答。
  • 持续厄瑞奴单抗组第12周未应答者中20.7%(17/82)转为≥50%应答者;安慰剂-厄瑞奴单抗组第12周未应答者中40.8%(42/103)转为≥50%应答者。
  • 第168周MMD自基线平均(SD)变化为-4.4(3.9)天。
  • 治疗中出现的高血压事件报告率为9.6%(3.9/100人年),便秘为6.7%(2.7/100人年)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The LIBERTY study assessed the efficacy and safety of erenumab in participants with episodic migraine (EM) and 2-4 prior preventive treatment failures. The results have been presented after 3 years of erenumab exposure in its open-label extension phase (OLEP). METHODS: Participants completing the 12-week double-blind treatment phase (DBTP) of the LIBERTY study could enter the OLEP and receive 140 mg of erenumab once monthly for 3 years. The main outcomes included the proportion of participants achieving ≥50% reduction in monthly migraine days (MMDs), the mean MMD change from baseline, and tolerability and safety. RESULTS: Overall, 240/246 (97.6%) participants entered the OLEP and 168/240 (70.0%) completed the study (85/118 continuing erenumab [n = 1 lost during follow-up]; 83/122 switching from placebo [n = 2 lost during follow-up]). In the overall population, 79/151 participants (52.3%) with valid data points achieved ≥50% reduction in MMDs at week 168 (i.e., responders). In the continuous erenumab group, 35/117 participants (29.9%) were ≥50% responders at week 12 of the DBTP and 26/35 (74.3%) remained ≥50% responders in at least half of OLEP visits. Of the 82/117 participants (70.1%) not achieving responder status at week 12 in the continuous erenumab group, 17/82 (20.7%) converted to ≥50% responders in at least half of OLEP visits. Of 103/120 participants (85.8%) not achieving responder status at week 12 in the placebo-erenumab group, 42/103 (40.8%) converted to ≥50% responders in at least half of OLEP visits after switching to erenumab. Overall, the mean (SD) MMD change from baseline showed sustained improvement over 3 years (-4.4 [3.9] days at week 168). The most common treatment-emergent AEs (per 100 person-years) were nasopharyngitis (28.8), influenza (7.5), and back pain (5.8). Overall, 9.6% (3.9 per 100 person-years) and 6.7% (2.7 per 100 person-years) of participants reported events of treatment-emergent hypertension and constipation, respectively. The safety and tolerability profile remained consistent with earlier studies. DISCUSSION: Erenumab (140 mg) showed sustained efficacy over 3 years in participants with EM and 2-4 prior preventive treatment failures. No new safety signals were observed. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT03096834.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Reuter U, Goadsby PJ, Ferrari MD, et al. Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study. Neurology. 2024. PMID: 38669638. doi:10.1212/WNL.0000000000209349

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。